Pang S, Taneja S, Dardashti K, et al. Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther. 1995;6:1417–1426.
Pang S, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR, et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res. 1997;57:495–499.
Latham JP, Searle PF, Mautner V, James ND . Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000;60:334–341.
Rodriguez R, Dannull J, Kaboo R, et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 1997;57:2559–2563.
Lu Y, Steiner MS . Transcriptionally regulated adenoviruses for prostate-specific gene therapy. World J Urol. 2000; 18:93–101.
Shi CX, Hitt M, Ng P, Graham FL . Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther. 2002;13:211–224.
Naldini L, Blomer U, Galley P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267.
Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA. 1996;93:11382–11388.
Stewart SA, Poon B, Jowett JB, Xie Y, Chen IS . Lentiviral delivery of HIV-1 Vpr protein induces apoptosis in transformed cells. Proc Natl Acad Sci USA. 1999;96: 12039–12043.
Uchida N . HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA. 1998;95:11939–11944.
Ericson C, Wictorin K, Lundberg C . Ex vivo and in vitro studies of transgene expression in rat astrocytes transduced with lentiviral vectors. Exp Neurol. 2002;173:22–30.
Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM . Development of a self-inactivating lentivirus vector. J Virol. 1998;72:8150–8157.
Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873–9880.
Yu D, Chen D, Chiu C, Razmazma B, Chow Y-H, Pang S . Prostate-specific targeting using PSA promoter based lentiviral. Cancer Gene Ther. 2001;8:628–635.
Pang S . Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther. 2000;7:991–996.
Dachs GU, Dougherty GJ, Stratford IJ, Chaplin DJ . Targeting gene therapy to cancer: a review. Oncol Res. 1997;9:313–325.
Ferrari G, Salvatori G, Rossi C, Cossu G, Mavilio F . A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther. 1995;6:733–742.
Vile RG, Diaz RM, Miller N, Mitchell S, Tuszyanski A, Russell SJ . Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology. 1995;214: 307–313.
Walther W, Stein U . Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting. J Mol Med. 1996;74:379–392.
Miller N, Whelan J . Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther. 1997;8:803–815.
Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman . The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991;5:1921–1930.
Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR . Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem. 1996; 271:7043–7051.
Cleutjens KB, van der Korput HA, van Eekelen CC, van Rooij HC, Faber PW, Trapman J . An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol. 1997;11:148–161.
Spitzweg C, Zhang S, Bergert ER, et al. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 1999;59:2136–2141.
Lee SE, McCadden J, Ferrer F, et al. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines. Anticancer Res. 2000;20:417–422.
Li Y, McCadden J, Ferrer F, et al. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res. 2002;62:2576–2582.
Pan D, Gunther R, Duan W, et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther. 2002;6:19–29.
Trono D . Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther. 2000;7:20–23.
Reiser J . Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 2000;7:910–913.
Kozarsky KF, Wilson JM . Gene therapy: adenovirus vectors. Curr Opin Genet Dev. 1993;3:499–503.
Brody SL, Crystal RG . Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci. 1994;716:90–101.
Tsai SY, Schillinger K, Ye X . Adenovirus-mediated transfer of regulable gene expression. Curr Opin Mol Ther. 2000;2:515–523.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4